FIELD: medicine.
SUBSTANCE: group of inventions is based on detecting high expression of EREG gene and protein accompanying colon cancer, pulmonary adenocarcinoma, pancreatic cancer, stomach cancer and kidney cancer. The group of inventions discloses the antibodies, which identify EREG protein, used for treating a malignant tumour. The group of inventions refers to agents and pharmaceutical compositions for the malignant tumour, containing the binding anti-EREG antibody as an active ingredient.
EFFECT: group of inventions is effective in treating the above tumours.
12 cl, 22 dwg, 5 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
| DRUGS FOR CANCER TREATMENT AND/OR PREVENTION | 2011 |
|
RU2624029C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING MALIGNANT GROWTHS | 2009 |
|
RU2498819C2 |
| ANTIBODY AGAINST MALIGNANT CELL, ANTI-CANCER DRUG AND METHOD FOR TESTING MALIGNANT NEOPLASM | 2015 |
|
RU2753512C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT OR PREVENTION | 2013 |
|
RU2631804C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2012 |
|
RU2611197C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| MOLECULES WHICH BIND TO 4-1BB | 2011 |
|
RU2710717C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2610428C2 |
